Lianghe Jiao1, Jing Wei2, Jun Ye3, Chuanmeng Zhang3. 1. Department of Thyroid and Breast Surgery, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China. 2. Department of Obstetrics and Gynecology, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China. 3. The Center for Translational Medicine, Taizhou People's Hospital, Taizhou, 225300 Jiangsu Province, China.
Abstract
METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.
METHODS: We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. RESULTS: Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival (HR = 1.68, 95% CI: 1.24-2.27, P = 0.001) and disease-free survival (HR = 1.88, 95% CI: 1.31-2.70, P = 0.001). In addition, high PRDX1 expression was associated with large tumor size (OR = 1.69, 95% CI: 1.07-2.68, P = 0.025), advanced TNM stage (OR = 2.26, 95% CI: 1.24-4.13, P = 0.008), and poor tumor differentiation (OR = 0.59, 95% CI: 0.44-0.81, P = 0.001). CONCLUSIONS: PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.
Authors: Bokyung Kim; Yeon Soo Kim; Hye-Mi Ahn; Hyo Jin Lee; Min Kyu Jung; Hyun Yong Jeong; Dong Kyu Choi; Jun Hyeog Lee; Sang-Rae Lee; Jin Man Kim; Dong-Seok Lee Journal: Int J Oncol Date: 2017-05-19 Impact factor: 5.650
Authors: Carola A Neumann; Daniela S Krause; Christopher V Carman; Shampa Das; Devendra P Dubey; Jennifer L Abraham; Roderick T Bronson; Yuko Fujiwara; Stuart H Orkin; Richard A Van Etten Journal: Nature Date: 2003-07-31 Impact factor: 49.962
Authors: Joo-Heon Kim; Paul N Bogner; Nithya Ramnath; Yoorim Park; Jihnhee Yu; Young-Mee Park Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531